期刊文献+

卡培他滨对食管癌细胞系EC9706细胞毒性和放射增敏作用的研究 被引量:5

Cytotoxic effect and radiosensitivity of capecitabine on esophageal carcinoma cell line EC9706
下载PDF
导出
摘要 目的:探讨卡培他滨对食管癌细胞系EC9706细胞毒性和放射增敏作用。方法:取健康成年家兔1只,以卡培他滨141mg/kg,对其进行灌胃,分别于灌胃前、后2.5~3h,取耳缘静脉血8~10mL,不加抗凝剂,并防止溶血和细菌污染,离心取血清-20℃保存备用;用CCK8分别检测不同量的加药血清和对照血清对食管癌细胞系EC9706细胞毒性,同时观察不同量的加药血清对食管癌细胞系EC9706的放射增敏作用。结果:加药血清对食管癌细胞系EC9706细胞有明显的抑制作用,其抑制作用48h达到高峰,2、4、6、8和10μL血清作用细胞48h后抑制率分别为14.29%、23.96%、50.59%、52.16%和53.96%(P均为0.00),72h其细胞毒性无增加;加药血清孵育2.5h后,在相同放射剂量作用下,不同量血清组的OD值均显著低于对照组(P值均为0.00),其增敏作用无明显的剂量依赖性。结论:卡培他滨对食管癌细胞系EC9706有明显的细胞毒性和放射增敏作用。 OBJECTIVE: To investigate the cytotoxic and radiosensitizing effect of capecitabine on esophageal carcinoma cell line EC9706. METHODS: One healthy adult rabbit was treated with oral administration of capecitabine in a dose of 141 mg/kg, amd before and after 2.5 3 hours of that, 8--10 mL blood was drew from the super ficial vein of the ear respectively, being no anticoagulant, avoiding hemolysis and infection, and the serum was collected after centrifuged, and it was reserved at --20 ℃. Cytotoxic effects of different doses of the serum on EC9706 cell line were evaludted respectively by using CCK 8 assay, and the radiosensitizing effects of different doses of the serum combining with different doses of irradiation were evaludted by using the same way. RESULTS: The serum treated with capecitabine obviously restrained EC9706 cell line. The peak of the inhibitory rate was at 48 hours. Being exposed to 2,4,6,8,10 μL of the serum, the inhibitory rates of the cell growth were 14.3%, 23.0%, 50.6%, 52.2% and 54.0% respeitively (P=0.00), The serum showed no more inhibitory effect at 72 hours. Under the same irradiation, OD of EC9706 cell line exposed to different doses of the serum treated with eapecitabine was obviously lower than that of the control group (P= 0.00), but the the radiosensitizing effect did not depent on the doses of the serum treated with capecitabine. CONCLUSION: Capecitabine has a significant cytotoxic and radiosensitizing effect on esophageal carcinoma cell line EC9706.
出处 《中华肿瘤防治杂志》 CAS 2008年第17期1302-1304,1318,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 河南省科技攻关课题(072102310086)
关键词 食管肿瘤 卡培他滨 EC9706细胞 放射增敏 esophageal neoplasms capecitabine EC9706 cell line radiosensitivity
  • 相关文献

参考文献11

  • 1毕经旺,史杰,周芙蓉,韩少荣,刘欣,狄剑士,王宝成.卡培他滨联合草酸铂治疗晚期胃肠道恶性肿瘤(附52例报告)[J].山东医药,2006,46(15):60-61. 被引量:5
  • 2Blanquicett C, Gillesple G Y, Nabors L B, et al. Induction of thymidine phosphorylase in both irradiated and shielded, contra lateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation[J]. Mol Cancer Ther, 2002, 1(12): 1139-1145.
  • 3Rich T A, Shepard R. COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas [J]. AmJ ClinOncol, 2003, 26(4): S110- S113.
  • 4Ballonoff A, Kavanagh B, MeCarter M, et al. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer., a phase Ⅱ trial[J]. Am J Clin Oncol, 2008, 31(3): 264-270.
  • 5Saif M W, Black G, Roy S, et al. Phase Ⅱ study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase[J]. Cancer J, 2007, 13(4) :247-256.
  • 6韩亚玲,魏芳,徐昕,蔡岩,陈宝生,王洁,夏书华,胡海,黄晓平,汉雨生,吴旻,王明荣.人食管鳞癌细胞系EC9706的建立及其比较基因组杂交分析[J].中华医学遗传学杂志,2002,19(6):455-457. 被引量:14
  • 7张卓然.细胞培养学与细胞培养技术[M].上海:上海科学技术出版社,2004:424.
  • 8时昌文,李杰,赵霞,曹莉莉,孙京杰.丙戊酸钠对肝癌细胞系HepG2的生长抑制作用[J].中华肿瘤防治杂志,2007,14(7):510-513. 被引量:12
  • 9颜伟,丁国富,李斌,董燕,李军,和生琦,罗平,周红,庞学利.CpG ODN107增强人脑胶质瘤细胞放射敏感性的研究[J].中华肿瘤防治杂志,2007,14(7):481-484. 被引量:7
  • 10Kvols L K. Radiation sensitizers: A selective review of targeting DNAand non-DNA targets[J]. J Nucl Med, 2005, 21 (4): 187s-190s.

二级参考文献34

  • 1周同冲,林晓丹,宋先璐,王兆武.石上柏联合放射治疗晚期鼻咽癌的临床观察[J].中华肿瘤防治杂志,2006,13(10):772-773. 被引量:6
  • 2李二妮,刘云鹏,侯科佐,李光.蟾蜍灵对人鼻咽癌细胞CNE-1的放射增敏作用[J].中华肿瘤防治杂志,2006,13(13):978-980. 被引量:7
  • 3李连弟,鲁凤珠.1990—1992年中国恶性肿瘤死亡流行分布情况分析[J].中华肿瘤杂志,1996,18(6):403-407. 被引量:227
  • 4宿远 王秀琴 等.人食管癌细胞在建系过程中的演变[J].中华肿瘤杂志,1988,10:410-413.
  • 5Diaz-Rubio E, Evans J, Tabernero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I , doseescalation study in patients with advanced or metastatic solid tumors[J]. Ann Onco, 2002, 13(4): 558-565.
  • 6Me-Gavin JK,Goa KL, Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer[J]. Drugs,2001,61(15):2309-2326.
  • 7Armand JP, Boige V, Raymond E,et al. Oxaliplatin in colorectal cancer : an overview [J]. Semin Oncol, 2000,27 (suppl 10): 96-104.
  • 8Extra JM, Marty M, Brienza S, et al. Pharmacokinetics and safety profile of oxaliplatin [J]. Semin Oncol, 1998,25 (suppl 5) :13-22.
  • 9Machover D, Diaz-Rubio E, de Gramont Aet al. Two consecutive phase Ⅰ studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines[J]. Ann Oncol ,1996,7(1):95-98.
  • 10de Gramont A, Figer M, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer[J]. J Clin Oncol, 2000,18(16): 2938-2947.

共引文献40

同被引文献50

引证文献5

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部